Blood Test Shows 90%+ Accuracy in Detecting Deadly Brain Tumour – Glioblastoma

A new blood test offering over 90% accuracy in detecting glioblastoma, an aggressive and often fatal brain tumour, is showing promise as a potential game-changer in diagnosis and treatment monitoring. The test, developed by researchers at the University of Manchester in collaboration with Danish teams, identifies specific protein signatures in the blood linked to the presence and behaviour of the tumour. Currently, diagnosing glioblastoma relies heavily on MRI scans and often requires invasive surgical biopsies to confirm the diagnosis and guide treatment decisions.

The research, published in Neuro-oncology Advances, focuses on identifying proteins that are altered in both the blood plasma and within the tumour tissue itself. This “Nano-omics” approach, as the researchers call it, allows for a more comprehensive understanding of the disease and how it responds to therapy. The study involved analysing blood samples from patients with glioblastoma during various stages of treatment – surgery, radiotherapy, and chemotherapy – to validate the test’s accuracy.

Understanding Glioblastoma: A Complex Challenge

Glioblastoma (GBM) is the most common and aggressive primary brain tumour in adults. According to the American Cancer Society, approximately 14,300 Americans are diagnosed with GBM each year. The standard treatment involves surgery, followed by radiation therapy and chemotherapy, but even with aggressive treatment, the prognosis remains poor, with a median survival of around 15-18 months. One of the major hurdles in treating glioblastoma is its inherent heterogeneity – tumours can vary significantly in their genetic makeup and how they respond to treatment, even within the same patient.

Professor Petra Hamerlik, chair of translational neuro-oncology at the University of Manchester and lead researcher on the project, emphasizes the historical difficulty in early diagnosis. “Glioblastoma is one of the most devastating cancers we face,” she stated. “The lack of reliable tests has been a major barrier to earlier diagnosis and treatment response monitoring.” The current diagnostic pathway often involves multiple visits to a general practitioner before an MRI scan is ordered, potentially delaying crucial intervention. Professor Hamerlik notes that patients often consult their doctors six to eight times before being referred for brain imaging.

How the Blood Test Works: A ‘Stable Signal’ in a Complex Disease

The new blood test doesn’t look for a single biomarker, but rather a combination of two proteins that, when present in altered levels, strongly indicate the presence of a glioblastoma. What makes this approach particularly promising is the consistency of the signal, even as the tumour evolves and changes over time. “What is remarkable about our findings is that, despite these tumours being very different in genetic create-up and constantly evolving, the signal in the blood is stable, robust and highly informative,” explains Professor Hamerlik. This stability is crucial for monitoring treatment response and detecting recurrence.

The researchers utilized a technique called mass spectrometry to analyze the nanoparticle biomolecule corona in blood samples. This allowed them to identify subtle changes in protein levels associated with the presence of the tumour. The study also found a significant overlap – over 30% – between the proteins identified in the blood and those found within the tumour tissue itself, further validating the test’s accuracy. Related research, highlighted in PubMed, also points to the role of axonal injury as a driver of glioblastoma progression, suggesting potential avenues for therapeutic intervention beyond simply targeting the tumour cells themselves.

Beyond Glioblastoma: Expanding the Scope of the Test

While the initial focus of the research has been on glioblastoma, the researchers are now working to expand the test’s capabilities to detect other types of brain tumours. The underlying principle – identifying unique protein signatures in the blood – could potentially be applied to a wider range of cancers, offering a less invasive and more accessible diagnostic tool. The team is also investigating whether the blood test can be used to predict how patients will respond to different treatments, allowing for more personalized and effective care.

What Does This Signify for Patients?

The development of this blood test represents a significant step forward in the fight against glioblastoma. A non-invasive diagnostic tool could lead to earlier detection, faster treatment initiation, and more effective monitoring of disease progression. The ability to track the tumour’s behaviour through a simple blood sample could also aid clinicians identify when a treatment is no longer working and adjust the treatment plan accordingly. Dr. Simon Newman, chief scientific officer at The Brain Tumour Charity, emphasizes the importance of early and accurate diagnosis, stating, “This research therefore marks a significant step towards a simple blood test that could help clinicians detect glioblastoma and monitor how patients are responding to treatment in real time.”

Limitations and Next Steps

It’s important to note that this research is still in its early stages. While the test demonstrated over 90% accuracy in the study, further validation is needed in larger and more diverse patient populations. The researchers are currently working to refine the test and standardize the procedures for sample collection and analysis. The next steps involve conducting clinical trials to assess the test’s performance in a real-world setting and to determine its impact on patient outcomes. The team is also exploring the possibility of developing a point-of-care test that could be used in a doctor’s office or even at home.

The ultimate goal is to integrate this blood test into routine clinical practice, providing clinicians with a valuable tool for diagnosing and managing glioblastoma and other brain tumours. This could lead to improved survival rates and a better quality of life for patients affected by these devastating diseases. Further research is also being conducted into oscillatory gene expression in glioblastoma, as detailed by research at the University of Manchester, which may provide further insights into the underlying mechanisms of the disease and identify new therapeutic targets.